The objective of this BAA is to support the pre-clinical development of novel vaccine adjuvants towards licensure for human use. For the purposes of this solicitation, vaccine adjuvants are defined using the U.S. Food and Drug Administration (FDA) definition: Vaccine adjuvants are agents added to, or used in conjunction with, vaccine antigens to augment or potentiate, and possibly target the specific immune response to the antigen.

Please see the attached solicitation document for further details.